Pancreatic Cancer Research

ResearcherOspedale G.B. Morgagni - L.PierantoniActive in the last 2 years

Carlo Fabbri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0670-9910; OpenAlex author ID A5055595209. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 10

  1. Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. Co-author DOI 10.1007/s13304-026-02598-7↗
  2. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  3. European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data and Global Burden of Disease Study 2019. Co-author DOI 10.1016/j.pan.2023.09.001↗
  4. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  5. Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2022.04.011↗
  6. Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. Last author DOI 10.3390/cancers15010001↗
  7. Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. Co-author DOI 10.1007/s11033-020-05763-2↗
  8. Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.pan.2017.11.001↗
  9. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Co-author DOI 10.3233/cbm-170464↗
  10. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells. Co-author DOI 10.1177/1066896912475073↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Cucchetti · 3 shared papers, 2022–2023 · strength 0.52
  2. Giorgio Ercolani · 3 shared papers, 2022–2023 · strength 0.52
  3. Massimo Falconi · 3 shared papers, 2022–2024 · strength 0.50
  4. Stefano Crippa · 2 shared papers, 2022–2023 · strength 0.37
  5. Roberto Salvia · 2 shared papers, 2024–2026 · strength 0.34
  6. Cecilia Binda · 2 shared papers, 2022 · strength 0.32
  7. Gabriele Capurso · 2 shared papers, 2023–2024 · strength 0.32
  8. Michela Visani · 4 shared papers, 2013–2020 · strength 0.25
  9. Dario de Biase · 4 shared papers, 2013–2020 · strength 0.25
  10. Ilaria Tarantino · 1 shared paper, 2026 · strength 0.22
  11. Giuseppe Quero · 1 shared paper, 2026 · strength 0.22
  12. Sergio Alfieri · 1 shared paper, 2026 · strength 0.22
  13. Evaristo Maiello · 1 shared paper, 2026 · strength 0.22
  14. Ugo Boggi · 1 shared paper, 2026 · strength 0.22
  15. Giampaolo Tortora · 1 shared paper, 2026 · strength 0.22
  16. Michèle Milella · 1 shared paper, 2026 · strength 0.22
  17. Michele Reni · 1 shared paper, 2026 · strength 0.22
  18. Sirio Fiorino · 3 shared papers, 2018–2020 · strength 0.21
  19. Elio Jovine · 3 shared papers, 2018–2020 · strength 0.21
  20. Michele Masetti · 3 shared papers, 2018–2020 · strength 0.21
  21. Carlo Alberto Pacilio · 1 shared paper, 2023 · strength 0.19
  22. Giovanni Tallini · 3 shared papers, 2013–2020 · strength 0.19
  23. Giuseppe Malleo · 1 shared paper, 2024 · strength 0.13
  24. Valentina Arcangeli · 1 shared paper, 2024 · strength 0.13
  25. Alberto Larghi · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.